CN102170903B - 用于刺激免疫反应的产品和方法 - Google Patents

用于刺激免疫反应的产品和方法 Download PDF

Info

Publication number
CN102170903B
CN102170903B CN200980125581.9A CN200980125581A CN102170903B CN 102170903 B CN102170903 B CN 102170903B CN 200980125581 A CN200980125581 A CN 200980125581A CN 102170903 B CN102170903 B CN 102170903B
Authority
CN
China
Prior art keywords
cell
antigen
virus
hel
bcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980125581.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170903A (zh
Inventor
法存多·巴蒂斯塔
尤利娅·埃克尔-多尔纳
帕特里西亚·巴拉尔
温琴佐·塞伦多罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CN102170903A publication Critical patent/CN102170903A/zh
Application granted granted Critical
Publication of CN102170903B publication Critical patent/CN102170903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980125581.9A 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法 Expired - Fee Related CN102170903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
CN102170903A CN102170903A (zh) 2011-08-31
CN102170903B true CN102170903B (zh) 2016-04-06

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980125581.9A Expired - Fee Related CN102170903B (zh) 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法

Country Status (8)

Country Link
US (1) US20110280930A1 (enExample)
EP (3) EP2711021B1 (enExample)
JP (3) JP5721620B2 (enExample)
CN (1) CN102170903B (enExample)
AU (1) AU2009241645B2 (enExample)
CA (1) CA2723226A1 (enExample)
ES (1) ES2570973T3 (enExample)
WO (1) WO2009133378A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723226A1 (en) * 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6100762B2 (ja) 2011-06-02 2017-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膜で被包されたナノ粒子および使用方法
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP7094533B2 (ja) * 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
CN107708740A (zh) * 2015-06-10 2018-02-16 萨尔布吕肯大学 用于治疗b细胞恶性肿瘤的手段和方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017211316A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting the presence of mycobacterial material in a sample using at least two antigens
NL2017204B1 (en) 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
WO2018035303A1 (en) * 2016-08-17 2018-02-22 Orbis Health Solutions Llc Tumor-targeting bead vectors and methods of using the same
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
EP0598816B1 (en) 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
AU711183B2 (en) 1994-08-19 1999-10-07 Biotransplant Incorporated Genetically engineered swine cells
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1694301A4 (en) * 2003-12-02 2009-11-18 Cytimmune Sciences Inc METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
WO2006002642A2 (en) * 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
JP2008531672A (ja) * 2005-03-02 2008-08-14 イギリス国 医薬組成物
WO2007050668A1 (en) 2005-10-25 2007-05-03 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
CA2723226A1 (en) * 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B CELLS EXTRACT AND PRESENT IMMOBILIZATION ANTIGEN: IMPLICATIONS FOR AFFINITY DISCRIMINATION;BATISTA F D ET AL;《EMBO JOURNAL》;20000130;第19卷(第4期);第513-520页 *
Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen;PEDERSEN M K ET AL;《JOURNAL OF IMMUNOLOGICAL METHODS》;20060420;第311卷(第1-2期);第198-206页 *
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma;PAUL NEESON ET AL;《CANCER IMMUNOLOGY, IMMUNOTHERAPY》;20070918;第57卷(第4期);第493-505页 *
Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases.;JONES DAVID S;《CURRENT MEDICINAL CHEMISTRY 2005》;20051231;第12卷(第16期);第1887-1904页 *

Also Published As

Publication number Publication date
AU2009241645B2 (en) 2014-07-17
CN102170903A (zh) 2011-08-31
EP2711021A1 (en) 2014-03-26
US20110280930A1 (en) 2011-11-17
EP2711020A1 (en) 2014-03-26
WO2009133378A3 (en) 2009-12-23
JP5853068B2 (ja) 2016-02-09
JP2015038066A (ja) 2015-02-26
ES2570973T3 (es) 2016-05-23
EP2711020B1 (en) 2016-08-10
EP2288381A2 (en) 2011-03-02
WO2009133378A2 (en) 2009-11-05
HK1190942A1 (en) 2014-07-18
JP2015028023A (ja) 2015-02-12
AU2009241645A1 (en) 2009-11-05
CA2723226A1 (en) 2009-05-11
JP5721620B2 (ja) 2015-05-20
EP2711021B1 (en) 2016-03-09
JP2011519847A (ja) 2011-07-14
HK1191548A1 (en) 2014-08-01
HK1161542A1 (zh) 2012-07-27

Similar Documents

Publication Publication Date Title
CN102170903B (zh) 用于刺激免疫反应的产品和方法
Ouaissi et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection
CN107670031A (zh) 利用阳离子脂质刺激免疫应答
US12246097B2 (en) Nanoparticle vaccine adjuvant and methods of use thereof
CN116212048A (zh) 纳米颗粒的细胞表面偶联
AU2012357968B2 (en) Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses
WO2014198184A1 (zh) 蛋白-细胞偶联物、其制备方法和用途
US20120328660A1 (en) Immunogenic compositions useful in provoking an integrated response to tumor antigens
US8466259B2 (en) Adjuvants
JP2002511421A (ja) Cd−1抗原およびt細胞刺激化合物を含むワクチン組成物およびその使用方法
AU2014250631B2 (en) Products and methods for stimulating an immune response
HK1161542B (en) Products and methods for stimulating an immune response
US20230190920A1 (en) Compositions and methods for long-lasting germinal center responses to a priming immunization
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
EP3650466A1 (en) In vitro production of high affinity monoclonal antibodies
Flannigan Characterization of adjuvant properties of microparticulate beta-glucan

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161542

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151016

Address after: English Marlowe

Applicant after: Cancer Rec Tech Ltd.

Address before: London, England

Applicant before: Cancer Rec Tech Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20170505

CF01 Termination of patent right due to non-payment of annual fee